Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity

US11155559B2 · kind B2 · utility

Assignee

• CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED · CN

Inventors

• Yuanshan Yao · Shanghai, CN
• Li Zhang · New Milford, US
• Zhaoguo Chen · Shanghai, CN
• Lele ZHAO · Shanghai, CN
• Lingyun WU · Shanghai, CN
• Shuhui CHEN · Shanghai, CN

Key dates

• Filing date: Jul 18, 2018
• Grant date: Oct 26, 2021
• Expiry date: Jul 18, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.